Medical

Displaying 1 - 10 of 749

Optogenetics fine-tuned

Optogenetics fine-tuned
Currently, optogenetics is a blunt-force instrument for manipulating neural activity, which limits its usefulness in the delicate environment of the brain. Researchers have demonstrated that optogenetics can be used as a finely tempered tool to observe and manipulate neural activity. Recent reports have emerged providing the opportunity to balance out excitation and inhibition of neural circuits using optogenetic techniques.
18th January 2017

Nanoparticles for drug delivery into the skin

Nanoparticles for drug delivery into the skin
Nanoparticles have emerged as important vehicles in drug delivery. Understanding the relationship between their structure and efficiency is central for maximising skin permeation. Systemic drug delivery often takes place through the skin due to its ease of use and better patient compliance. However, the outermost layer of the skin, the stratum corneum (SC) poses a significant barrier to drug application.
18th January 2017

Analysing molecular mechanisms behind cognition

Analysing molecular mechanisms behind cognition
EU-funded scientists have investigated the role of synapse dysfunction in intellectual development and shed more light on the molecular mechanisms behind cognition. The aim MASDUHID (Molecular analysis of synaptic dysfunctions underlying human intellectual disabilities) project was to understand the synaptic molecular dysfunction associated with intellectual disorders, especially non-syndromic intellectual disability (NSID).
18th January 2017


How solvents affect the skin

How solvents affect the skin
Researchers at Lund University in Sweden have developed a method that makes it possible to see how individual molecules from solvents in skin creams, medicated ointments and cleaning products affect and interact with the skin’s own molecules. In the study, the researchers have examined how molecules added to the skin through various liquids and creams affect the skin, and how the same molecules are affected by being inside the skin.
18th January 2017

Antibody design opens door for brain treatments

Antibody design opens door for brain treatments
Immunotherapy has proven to be effective against many serious diseases. But to treat diseases in the brain, the antibodies must first get past the obstacle of the blood-brain barrier. In a new study, a research group at Uppsala University describes their development of a new antibody design that increases brain uptake of antibodies almost 100-fold. Immunotherapy entails treatment with antibodies; it is the fastest growing field in pharmaceutical development.
17th January 2017

Wearable sensors can tell when you are getting ill

Wearable sensors can tell when you are getting ill
  Wearable sensors that monitor heart rate, activity, skin temperature and other variables can reveal a lot about what is going on inside a person, including the onset of infection, inflammation and even insulin resistance, according to a study by researchers at the Stanford University School of Medicine.
13th January 2017

UW-Madison launches Microbiome Initiative

UW-Madison launches Microbiome Initiative
A UW–Madison Microbiome Initiative comes with $1 million in grant funding administered by the vice chancellor for research and graduate education to support interdisciplinary research, infrastructure, and research community enhancements related to the microbiome. “Microbiome science has the potential to revolutionise areas such as health care, agriculture, biomanufacturing, environmental management, and more,” says Marsha Mailick, UW–Madison’s vice chancellor for research and graduate education.
12th January 2017

Drug delivery system for the treatment of Parkinson’s

Drug delivery system for the treatment of Parkinson’s
Renishaw’s latest drug delivery system, to be used in partnership with Herantis Pharma Plc’s drug candidate CDNF for the treatment of Parkinson’s disease, is about to enter phase 1-2 clinical trials. The study will be supported by a €6 million grant from Horizon 2020, the European Union’s Framework Programme for Research and Innovation. Neurodegenerative diseases such as Parkinson’s are notoriously difficult to target with medication due to the protective role of the blood-brain barrier.
11th January 2017

Hand-powered blood centrifuge aids diagnosis and treatment

Hand-powered blood centrifuge aids diagnosis and treatment
Here’s how to build a whirligig: Thread a loop of twine through two holes in a button. Grab the loop ends, then rhythmically pull. As the twine coils and uncoils, the button spins at a dizzying speed. Inspired by a toy, Stanford bioengineers have developed an inexpensive, human-powered blood centrifuge that will enable precise diagnosis and treatment of diseases like malaria, African sleeping sickness and tuberculosis in the poor, off-the-grid regions where these diseases are most prevalent.
11th January 2017

Foster Corporation appointed a distributor for healthcare markets

Foster Corporation appointed a distributor for healthcare markets
Appointed as a North American distributor of Solvay’s Udel Polysulfone (PSU) and Radel Polyphenylsulfone (PPSU) resins for healthcare markets is Foster Corporation, which will also include unmodified polymers and standard colour formulations currently offered by Solvay.
10th January 2017


Medical documents


Sign up to view our publications

Sign up

Sign up to view our downloads

Sign up

Mobile World Congress 2017
27th February 2017
Spain Fira Gran Via and Fira Montjuïc
embedded world 2017
14th March 2017
Germany Nürnberg Messe
electronica China 2017
14th March 2017
China Shanghai New International Expo Centre